Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
PharmacoEconomics
Published in: PharmacoEconomics 8/2012

01-08-2012 | Review Article

Economic Evaluations of Childhood Influenza Vaccination

A Critical Review

Authors: Dr Anthony T. Newall, Mark Jit, Philippe Beutels

Published in: PharmacoEconomics | Issue 8/2012

Login to get access

Abstract

The potential benefits of influenza vaccination programmes targeted at children have gained increasing attention in recent years.
We conducted a literature search of economic evaluations of influenza vaccination in those aged ≤18 years. The search revealed 20 relevant articles, which were reviewed. The studies differed widely in terms of the costs and benefits that were included. The conclusions were generally favourable for vaccination, but often applied a wider perspective (i.e. including productivity losses) than the reference case for economic evaluations used in many countries. Several evaluations estimated outcomes from a single-year epidemiological study, which may limit their validity given the year-to-year variation in influenza transmissibility, virulence, vaccine match and prior immunity. Only one study used a dynamic transmission model able to fully incorporate the indirect herd protection to the wider community.
The use of dynamic models offers great scope to capture the population-wide implications of seasonal vaccination efforts, particularly those targeted at children.
Literature
1.
Fiore AE, Shay DK, Broder K, et al. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. MMWR Recomm Rep 2009; 58 (RR-8): 1–52PubMed
2.
Centers for Disease Control and Prevention. Seasonal influenza vaccination coverage among children aged 6 months-18 years: eight immunization information system sentinel sites, United States, 2009–10 influenza season. MMWR Morb Mortal Wkly Rep 2010; 59(39): 1266–9
3.
Mereckiene J, Cotter S, Nicoll A, et al. National seasonal influenza vaccination survey in Europe, 2008. Euro Surveill 2008; 13(43): 19017PubMed
4.
5.
Monto AS, Koopman JS, Longini Jr IM. Tecumseh study of illness: XIII. Influenza infection and disease, 1976–1981. Am J Epidemiol 1985; 121(6): 811–22
6.
Mossong J, Hens N, Jit M, et al. Social contacts and mixing patterns relevant to the spread of infectious diseases. PLoS Med 2008; 5(3): e74PubMedCrossRef
7.
Loughlin J, Poulios N, Napalkov P, et al. A study of influenza and influenza-related complications among children in a large US health insurance plan database. Pharmacoeconomics 2003; 21(4): 273–83PubMedCrossRef
8.
Bhat N, Wright JG, Broder KR, et al. Influenza-associated deaths among children in the United States, 2003–2004. N Engl J Med 2005; 353(24): 2559–67PubMedCrossRef
9.
Thompson WW, Shay DK, Weintraub E, et al. Influenza-associated hospitalizations in the United States. JAMA 2004; 292(11): 1333–40PubMedCrossRef
10.
Newall AT, Scuffham PA. Influenza-related disease: the cost to the Australian healthcare system. Vaccine 2008; 26(52): 6818–23PubMedCrossRef
11.
Thompson WW, Weintraub E, Dhankhar P, et al. Estimates of US influenza-associated deaths made using four different methods. Influenza Other Respi Viruses 2009; 3(1): 37–49PubMedCrossRef
12.
Savidan E, Chevat C, Marsh G. Economic evidence of influenza vaccination in children. Health Policy 2008; 86(2–3): 142–52PubMedCrossRef
13.
14.
Loeb M, Russell ML, Moss L, et al. Effect of influenza vaccination of children on infection rates in Hutterite communities: a randomized trial. JAMA 2010; 303(10): 943–50PubMedCrossRef
15.
Reichert TA, Sugaya N, Fedson DS, et al. The Japanese experience with vaccinating schoolchildren against influenza. N Engl J Med 2001; 344(12): 889–96PubMedCrossRef
16.
Kelly H, Newall AT. Mortality benefits of influenza vaccination in elderly people. Lancet Infect Dis 2008; 8(8): 462–3PubMedCrossRef
17.
Simonsen L, Taylor RJ, Viboud C, et al. Mortality benefits of influenza vaccination in elderly people: an ongoing controversy. Lancet Infect Dis 2007; 7(10): 658–66PubMedCrossRef
18.
Jefferson T, Di Pietrantonj C, Rivetti A, et al. Vaccines for preventing influenza in healthy adults. Cochrane Database Syst Rev 2010; 7: CD001269PubMed
19.
Belshe RB, Edwards KM, Vesikari T, et al. Live attenuated versus inactivated influenza vaccine in infants and young children. N Engl J Med 2007; 356(7): 685–96PubMedCrossRef
20.
Ambrose CS, Levin MJ, Belshe RB. The relative efficacy of trivalent live attenuated and inactivated influenza vaccines in children and adults. Influenza Other Respi Viruses 2011; 5(2): 67–75PubMedCrossRef
21.
Ashkenazi S, Vertruyen A, Aristegui J, et al. Superior relative efficacy of live attenuated influenza vaccine compared with inactivated influenza vaccine in young children with recurrent respiratory tract infections. Pediatr Infect Dis J 2006; 25(10): 870–9PubMedCrossRef
22.
Fleming DM, Crovari P, Wahn U, et al. Comparison of the efficacy and safety of live attenuated cold-adapted influenza vaccine, trivalent, with trivalent inactivated influenza virus vaccine in children and adolescents with asthma. Pediatr Infect Dis J 2006; 25(10): 860–9PubMedCrossRef
23.
Esposito S, Principi N. The rational use of influenza vaccines in healthy children and children with underlying conditions. Curr Opin Infect Dis 2009; 22(3): 244–9PubMedCrossRef
24.
25.
Riddiough MA, Sisk JE, Bell JC. Influenza vaccination: cost-effectiveness and public policy. JAMA 1983; 249(23): 3189–95PubMedCrossRef
26.
White T, Lavoie S, Nettleman MD. Potential cost savings attributable to influenza vaccination of school-aged children. Pediatrics 1999; 103(6): e73PubMedCrossRef
27.
Cohen GM, Nettleman MD. Economic impact of influenza vaccination in preschool children. Pediatrics 2000; 106(5): 973–6PubMedCrossRef
28.
Dayan GH, Nguyen VH, Debbag R, et al. Cost-effectiveness of influenza vaccination in high-risk children in Argentina. Vaccine 2001; 19(30): 4204–13PubMedCrossRef
29.
Fitzner KA, Shortridge KF, McGhee SM, et al. Cost-effectiveness study on influenza prevention in Hong Kong. Health Policy 2001; 56(3): 215–34PubMedCrossRef
30.
Luce BR, Zangwill KM, Palmer CS, et al. Cost-effectiveness analysis of an intranasal influenza vaccine for the prevention of influenza in healthy children. Pediatrics 2001; 108(2): E24PubMedCrossRef
31.
Turner D, Wailoo A, Nicholson K, et al. Systematic review and economic decision modelling for the prevention and treatment of influenza A and B. Health Technol Assess 2003; 7(35): 1–170
32.
Hall JL, Katz BZ. Cost of influenza hospitalization at a tertiary care children’s hospital and its impact on the cost-benefit analysis of the recommendation for universal influenza immunization in children age 6 to 23 months. J Pediatr 2005; 147(6): 807–11PubMedCrossRef
33.
Meltzer MI, Neuzil KM, Griffin MR, et al. An economic analysis of annual influenza vaccination of children. Vaccine 2005; 23(8): 1004–14PubMedCrossRef
34.
Weycker D, Edelsberg J, Halloran ME, et al. Populationwide benefits of routine vaccination of children against influenza. Vaccine 2005; 23(10): 1284–93PubMedCrossRef
35.
Esposito S, Marchisio P, Bosis S, et al. Clinical and economic impact of influenza vaccination on healthy children aged 2–5 years. Vaccine 2006; 24(5): 629–35PubMedCrossRef
36.
Prosser LA, Bridges CB, Uyeki TM, et al. Health benefits, risks, and cost-effectiveness of influenza vaccination of children. Emerg Infect Dis 2006; 12(10): 1548–58PubMedCrossRef
37.
Salo H, Kilpi T, Sintonen H, et al. Cost-effectiveness of influenza vaccination of healthy children. Vaccine 2006; 24(23): 4934–41PubMedCrossRef
38.
Skowronski DM, Woolcott JC, Tweed SA, et al. Potential cost-effectiveness of annual influenza immunization for infants and toddlers: experience from Canada. Vaccine 2006; 24(19): 4222–32PubMedCrossRef
39.
Pisu M, Meltzer MI, Hurwitz ES, et al. Household-based costs and benefits of vaccinating healthy children in daycare against influenza virus: results from a pilot study. Pharmacoeconomics 2005; 23(1): 55–67PubMedCrossRef
40.
Hibbert CL, Piedra PA, McLaurin KK, et al. Cost-effectiveness of live-attenuated influenza vaccine, trivalent in preventing influenza in young children attending daycare centres. Vaccine 2007; 25(47): 8010–20PubMedCrossRef
41.
Marchetti M, Kühnel UM, Colombo GL, et al. Cost-effectiveness of adjuvanted influenza vaccination of healthy children 6 to 60 months of age. Hum Vaccin 2007; 3(1): 14–22PubMedCrossRef
42.
Navas E, Salleras L, Domínguez A, et al. Cost-effectiveness analysis of inactivated virosomal subunit influenza vaccination in children aged 3–14 years from the provider and societal perspectives. Vaccine 2007; 25(16): 3233–9PubMedCrossRef
43.
Luce BR, Nichol KL, Belshe RB, et al. Cost-effectiveness of live attenuated influenza vaccine versus inactivated influenza vaccine among children aged 24–59 months in the United States. Vaccine 2008; 26(23): 2841–8PubMedCrossRef
44.
Schmier J, Li S, King Jr JC, et al. Benefits and costs of immunizing children against influenza at school: an economic analysis based on a large-cluster controlled clinical trial. Health Affairs 2008; 27(2): w96–104PubMedCrossRef
45.
Salleras L, Navas E, Domínguez A, et al. Economic benefits for the family of inactivated subunit virosomal influenza vaccination of healthy children aged 3–14 years during the annual health examination in private paediatric offices. Vaccine 2009; 27(25–26): 3454–8PubMedCrossRef
46.
Jefferson T, Rivetti A, Harnden A, et al. Vaccines for preventing influenza in healthy children. Cochrane Database Syst Rev 2008; 2: CD004879PubMed
47.
Newall AT, Kelly H, Harsley S, et al. Cost effectiveness of influenza vaccination in older adults: a critical review of economic evaluations for the 50- to 64-year age group. Pharmacoeconomics 2009; 27(6): 439–50PubMedCrossRef
48.
Stephenson I, Nicholson KG. Influenza: vaccination and treatment. Eur Respir J 2001; 17(6): 1282–93PubMedCrossRef
49.
Navarro-Mari JM, Pérez-Ruiz M, Cantudo-Munoz P, et al. Influenza-like illness criteria were poorly related to laboratory-confirmed influenza in a sentinel surveillance study. J Clin Epidemiol 2005; 58(3): 275–9PubMedCrossRef
50.
Fujieda M, Maeda A, Kondo K, et al. Influenza vaccine effectiveness and confounding factors among young children. Vaccine 2008; 26(50): 6481–5PubMedCrossRef
51.
Keren R, Zaoutis TE, Saddlemire S, et al. Direct medical cost of influenza-related hospitalizations in children. Pediatrics 2006; 118(5): e1321–7PubMedCrossRef
52.
Lambert SB, Allen KM, Carter RC, et al. The cost of community-managed viral respiratory illnesses in a cohort of healthy preschool-aged children. Respir Res 2008; 9: 11PubMedCrossRef
53.
Kim SY, Goldie SJ. Cost-effectiveness analyses of vaccination programmes: a focused review of modelling approaches. Pharmacoeconomics 2008; 26(3): 191–215PubMedCrossRef
54.
Halloran ME, Longini IM, Cowart DM, et al. Community interventions and the epidemic prevention potential. Vaccine 2002; 20(27–28): 3254–62PubMed
55.
Basta NE, Chao DL, Halloran ME, et al. Strategies for pandemic and seasonal influenza vaccination of schoolchildren in the United States. Am J Epidemiol 2009; 170(6): 679–86PubMedCrossRef
56.
Vynnycky E, Pitman R, Siddiqui R, et al. Estimating the impact of childhood influenza vaccination programmes in England and Wales. Vaccine 2008; 26(41): 5321–30PubMedCrossRef
57.
Clemens J, Shin S, Ali M. New approaches to the assessment of vaccine herd protection in clinical trials. Lancet Infect Dis 2011; 11(6): 482–7PubMedCrossRef
58.
Hens N, Goeyvaerts N, Aerts M, et al. Mining social mixing patterns for infectious disease models based on a two-day population survey in Belgium. BMC Infectious Diseases 2009; 9: 5PubMedCrossRef
59.
Goeyvaerts N, Hens N, Ogunjimi B, et al. Estimating infectious disease parameters from data on social contacts and serological status. J Royal Stat Soc C-App 2010; 59(2): 255–77CrossRef
60.
Ogunjimi B, Hens N, Goeyvaerts N, et al. Using empirical social contact data to model person to person infectious disease transmission: an illustration for varicella. Math Biosci 2009; 218(2): 80–7PubMedCrossRef
61.
Bilcke J, Beutels P, Brisson M, et al. Accounting for methodological, structural, and parameter uncertainty in decision-analytic models: a practical guide. Med Decis Making 2011; 31(4): 675–92PubMedCrossRef
62.
Jit M, Brisson M. Modelling the epidemiology of infectious diseases for decision analysis: a primer. Pharmacoeconomics 2011; 29(5): 371–86PubMedCrossRef
63.
Carrat F, Flahault A. Influenza vaccine: the challenge of antigenic drift. Vaccine 2007; 25(39–40): 6852–62PubMedCrossRef
64.
Smith RD, Sach TH. Contingent valuation: what needs to be done? Health Econ Policy Law 2010; 5(1): 91–111PubMedCrossRef
65.
Polsky D, Willke RJ, Scott K, et al. Theory versus practice: a review of ‘willingness-to-pay’ in health and health care. Health Econ 2001; 10(1): 39–52CrossRef
66.
National Institute for Health and Clinical Excellence. Guide to the methods of technology appraisal. London: NICE, 2008
67.
Canadian Agency for Drugs and Technologies in Health. Guidelines for the economic evaluation of health technologies. Ottawa (ON): CADTH, 2006
68.
Knies S, Severens JL, Ament AJHA, et al. The transferability of valuing lost productivity across jurisdictions: differences between national pharmacoeconomic guidelines. Value Health 2010; 13(5): 519–27PubMedCrossRef
69.
Drummond M, Sculpher MJ, Torrance GW, et al. Methods for the economic evaluation of health care programmes. 3rd rev. ed. Oxford: Oxford University Press, 2005
70.
Griebsch I, Coast J, Brown J. Quality-adjusted life-years lack quality in pediatric care: a critical review of published cost-utility studies in child health. Pediatrics 2005; 115(5): e600–14PubMedCrossRef
71.
Brouwer WBF, Koopmanschap MA, Rutten FFH. Productivity costs measurement through quality of life? A response to the recommendation of the Washington Panel. Health Econ 1997; 6(3): 253–9PubMedCrossRef
72.
Tarn TY, Smith MD. Pharmacoeconomic guidelines around the world. ISPOR Connections 2004; 10(4): 5
73.
Newall AT, Viboud C, Wood JG. Influenza-attributable mortality in Australians aged more than 50 years: a comparison of different modelling approaches. Epidemiol Infect 2010; 138(6): 836–42PubMedCrossRef
74.
Influenza vaccines. Wkly Epidemiol Rec 2005; 80(33): 279–87
75.
Hoskins TW, Davies JR, Allchin A. Controlled trial of inactivated influenza vaccine containing the A/Hong Kong strain during an outbreak of influenza due to the A/England/42/72 strain. Lancet 1973; 2(7821): 116–20PubMedCrossRef
76.
Briscoe JH. The protective effect of influenza vaccine in a mixed influenza A and B epidemic in a boys’ boarding school. J R Coll Gen Pract 1977; 27(166): 28–31PubMed
77.
Claxton K, Sculpher M, McCabe C, et al. Probabilistic sensitivity analysis for NICE technology assessment: not an optional extra. Health Econ 2005; 14(4): 339–47PubMedCrossRef
78.
Neuzil KM, Zhu Y, Griffin MR, et al. Burden of interpandemic influenza in children younger than 5 years: a 25-year prospective study. J Infect Dis 2002; 185(2): 147–52PubMedCrossRef
79.
Newall AT, Wood JG, Oudin N, et al. Cost-effectiveness of pharmaceutical-based pandemic influenza mitigation strategies. Emerg Infect Dis 2010; 16(2): 224–30PubMedCrossRef
80.
Baguelin M, Hoek AJV, Jit M, et al. Vaccination against pandemic influenza A/H1N1v in England: a real-time economic evaluation. Vaccine 2010; 28(12): 2370–84PubMedCrossRef
81.
Gojovic MZ, Sander B, Fisman D, et al. Modelling mitigation strategies for pandemic (H1N1) 2009. CMAJ 2009; 181(10): 673–80PubMed
82.
Lee BY, Brown ST, Korch GW, et al. A computer simulation of vaccine prioritization, allocation, and rationing during the 2009 H1N1 influenza pandemic. Vaccine 2010; 28(31): 4875–9PubMedCrossRef
Metadata
Title
Economic Evaluations of Childhood Influenza Vaccination
A Critical Review
Authors
Dr Anthony T. Newall
Mark Jit
Philippe Beutels
Publication date
01-08-2012
Publisher
Springer International Publishing
Published in
PharmacoEconomics / Issue 8/2012
Print ISSN: 1170-7690
Electronic ISSN: 1179-2027
DOI
https://doi.org/10.2165/11599130-000000000-00000

Other articles of this Issue 8/2012

PharmacoEconomics 8/2012 Go to the issue

Original Research Article

A Parent-Child Dyad Approach to the Assessment of Health Status and Health-Related Quality of Life in Children with Asthma

Commentary

Valuing Children’s Health

Original Research Article

Cost Effectiveness of Guanfacine Extended Release as an Adjunctive Therapy to a Stimulant Compared with Stimulant Monotherapy for the Treatment of Attention-Deficit Hyperactivity Disorder in Children and Adolescents

Original Research Article

Developing Adolescent-Specific Health State Values for Economic Evaluation

Original Research Article

The Impact of Rotavirus Vaccination on Discounted Net Tax Revenue in Egypt

Original Research Article

Preference-Based Health-Related Quality-of-Life Outcomes in Children with Autism Spectrum Disorders